Inhibitors of interleukin-1β converting enzyme
US8119631B2 · kind B2 · utility
Assignee
Inventors
- Mark James Batchelor
- David Bebbington
- Guy Bemis
- Wolf Herman Fridman
- Roger John Gillespie
- Julian M. C. Golec
- Yong Gu
- David J. Lauffer
- David J. Livingston
- Saroop Singh Matharu
- Michael D. Mullican
- Mark A. Murcko
- Robert Murdoch
- Philip Nyce
- Andrea L. C. Robidoux
- Michael Su
- M. Woods Wannamaker
- Keith P. Wilson
- Robert E. Zelle
Key dates
| Filing date | May 24, 2010 |
| Grant date | Feb 21, 2012 |
| Priority date | — |
| Expiry date | May 24, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.